Andrew Feldhaus
About
Andrew Feldhaus is from Greater Seattle Area. Andrew works in the following industries: "Biotechnology Research". Andrew is currently Vice President Preclinical Development at Icosavax, Inc., located in Seattle, Washington, United States. In Andrew's previous role as a Senior Director Preclinical Development at Icosavax, Inc., Andrew worked in Seattle WA until Apr 2022. Prior to joining Icosavax, Inc., Andrew was a Director Target Biology at Alder BioPharmaceuticals and held the position of Director Target Biology at Bothell WA. Prior to that, Andrew was a Principal Scientist at Alder BioPharmaceuticals from Jul 2010 to Oct 2012. Andrew started working as Principal Scientist at ZymoGenetics in Apr 1998. From Jan 1998 to Jan 1998, Andrew was Contract at ICOS. Prior to that, Andrew was a Staff Scientist at Targeted Genetics from Jan 1993 to Jan 1998. Andrew started working as Post-Doctoral Fellow at University of Chicago-HHMI in Feb 1989.
You can find Andrew Feldhaus's email address at finalscout.com. FinalScout is a free professional database with over five hundred million business professional profiles and over two hundred million company profiles.
Andrew Feldhaus's current jobs
Andrew Feldhaus's past jobs
Manage multiple preclinical antibody therapeutics programs from discovery through IND. Involved in target selection, development of screening strategies, assay development and efficacy models in rodents and NHP. Extensive experience managing work with CROs.
Development of antibody therapeutics. New target development, project leader, Manage animal model studies via CROs.
Functional characterization of novel proteins to develop protein therapeutics. Managed transgenic mouse, knockout mouse, recombinant adenovirus and lentivirus programs. Joined the oncology department and developed RNAi technology for identification and validation of oncology Ab targets.
Conceived, constructed and evaluated a CD2/CD28 chimeric receptor and validated the receptor provided antigen specific CD8+ T cells costimulatory signals in response to antigen and LFA3 (ligand for CD2). Demonstrated a GM-CSFR/IL-2R chimeric receptor provided IL-2 receptor signaling in response to GM-CSF. This receptor was designed to provide a proliferative signal to antigen specific CD8+ T cells in response to antigen and GM-CSF. Evaluated series of inducible promoters to express IL-2 in activated CD8+ T cells. Constructs with these promoters were developed for patient specific gene therapy protocols. Developed small synthetic promoters (<100bp) for expression of large cDNAs in adeno-associated gene therapy vectors. Developed methods for efficient gene delivery to primary T cells using retroviruses.
Fellowship in the lab of Dr. Harinder Singh. Studied regulation of gene expression during B cell devlopment.